IN2014DN09817A - - Google Patents

Info

Publication number
IN2014DN09817A
IN2014DN09817A IN9817DEN2014A IN2014DN09817A IN 2014DN09817 A IN2014DN09817 A IN 2014DN09817A IN 9817DEN2014 A IN9817DEN2014 A IN 9817DEN2014A IN 2014DN09817 A IN2014DN09817 A IN 2014DN09817A
Authority
IN
India
Prior art keywords
active
formulation
skin
patient
occlusivity
Prior art date
Application number
Other languages
English (en)
Inventor
Hyder Aliyar
Robert O Huber
Gary L Loubert
Gerald K Schalau
Original Assignee
Dow Corning
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Corning filed Critical Dow Corning
Publication of IN2014DN09817A publication Critical patent/IN2014DN09817A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN9817DEN2014 2012-04-27 2014-11-19 IN2014DN09817A (enrdf_load_stackoverflow)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261639611P 2012-04-27 2012-04-27
PCT/US2013/030212 WO2013162723A1 (en) 2012-04-27 2013-03-11 Topical formulation compositions containing silicone based excipients to deliver actives to a substrate

Publications (1)

Publication Number Publication Date
IN2014DN09817A true IN2014DN09817A (enrdf_load_stackoverflow) 2015-07-31

Family

ID=48045040

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9817DEN2014 IN2014DN09817A (enrdf_load_stackoverflow) 2012-04-27 2014-11-19

Country Status (6)

Country Link
US (1) US20150141389A1 (enrdf_load_stackoverflow)
EP (1) EP2841106A1 (enrdf_load_stackoverflow)
JP (1) JP6093007B2 (enrdf_load_stackoverflow)
CN (1) CN104271160B (enrdf_load_stackoverflow)
IN (1) IN2014DN09817A (enrdf_load_stackoverflow)
WO (1) WO2013162723A1 (enrdf_load_stackoverflow)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105012228B (zh) * 2015-08-17 2018-04-20 郑州和济生物科技股份有限公司 防止疤痕形成及早期修复的玻尿酸硅凝胶组合物及制备方法
GB201616223D0 (en) * 2016-09-23 2016-11-09 University College Cardiff Consultants Limited Topical treatment patch
CA3053507A1 (en) * 2017-02-15 2018-08-23 Botanix Pharmaceuticals Ltd Compositions for treating acne
CN111432802A (zh) 2017-12-04 2020-07-17 强生消费者公司 含有非甾体抗炎药的局部用乳液组合物
US20190224137A1 (en) * 2018-01-24 2019-07-25 Botanix Pharmaceuticals Ltd. Cannabinoid Dosing Regime for Acne
BR112020014955A2 (pt) * 2018-01-24 2020-12-22 Botanix Pharmaceuticals Ltd Regime de dosagem de canabinoides para acne
AT521126A2 (de) * 2018-03-29 2019-10-15 Bcsk Biocid Gmbh Sprühpflasterzusammensetzung
WO2019213142A1 (en) * 2018-04-30 2019-11-07 Eleblend Llc Cosmetic compositions
US11304416B2 (en) * 2018-09-24 2022-04-19 Relevo Labs, Llc Cyclopentasiloxane and cationic biocide as a formulation additive to enhance persistent sanitizing and miscibility
CA3138195A1 (en) 2019-04-30 2020-11-05 Bayer Healthcare Llc Topical analgesic compositions
CA3138194A1 (en) 2019-04-30 2020-11-05 Bayer Healthcare Llc Topical analgesic gel compositions
TWI691343B (zh) * 2019-05-02 2020-04-21 邵明遠 液體繃帶組成物之用途
WO2021061913A1 (en) * 2019-09-27 2021-04-01 Encube Ethicals, Pvt. Ltd. Diclofenac sodium topical solution
US20240307416A1 (en) * 2021-07-29 2024-09-19 3M Innovative Properties Company Film-forming compositions comprising salicylic acid and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000063267A (ja) * 1998-08-21 2000-02-29 Senju Pharmaceut Co Ltd 経皮吸収貼付剤
FR2867682B1 (fr) * 2004-03-22 2009-06-05 Galderma Res & Dev Composition pharmaceutique anhydre associant un agent silicone et un principe actif solubilise.
FR2871699A1 (fr) * 2004-06-17 2005-12-23 Galderma Sa Composition de type emulsion inverse contenant du calcitrol et du 17-propionate de clobetasol, et ses utilisations en cosmetiques et en dermatologie
JP2008502647A (ja) * 2004-06-17 2008-01-31 ガルデルマ・ソシエテ・アノニム シリコーン剤、コルチコステロイドおよびビタミンdまたはその誘導体を含む乾癬治療用組成物
GB0506141D0 (en) * 2005-03-24 2005-05-04 Transphase Ltd A topical compostion and its uses
US20070207107A1 (en) * 2006-03-03 2007-09-06 Gareth Winckle Silicone based emulsions for topical drug delivery
EP3284470A1 (en) * 2006-11-15 2018-02-21 Arthritis Relief Plus Ltd. Topical formulation comprising comfrey extract
JP2010533186A (ja) * 2007-07-11 2010-10-21 ダウ・コーニング・コーポレイション 薬物を送達するための組成物
US20100092408A1 (en) * 2008-10-14 2010-04-15 Laurie Ellen Breyfogle Resilient personal care composition comprising polyalkyl ether containing siloxane elastomers
US20100099766A1 (en) * 2008-10-16 2010-04-22 Novartis Ag Topical NSAID compositions having sensate component
WO2011006100A1 (en) * 2009-07-09 2011-01-13 Crescendo Therapeutics, Llc Method of wound healing and scar modulation
US20130089577A1 (en) * 2010-03-11 2013-04-11 Joseph P. St. Laurent Novel ester containing compositions and methods

Also Published As

Publication number Publication date
CN104271160B (zh) 2017-08-08
WO2013162723A1 (en) 2013-10-31
EP2841106A1 (en) 2015-03-04
JP6093007B2 (ja) 2017-03-08
CN104271160A (zh) 2015-01-07
JP2015514801A (ja) 2015-05-21
US20150141389A1 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
IN2014DN09817A (enrdf_load_stackoverflow)
MX2021004546A (es) Composiciones de suministro de farmaco implantables y metodos de uso de las mismas.
MX2011013150A (es) Composicion farmaceutica para uso en oftalmologia medica y veterinaria.
BR112013008601A8 (pt) Formulações de emulsão de clevidipina contendo agentes antimicrobianos
BR112016014830A2 (pt) Conjugados de fármaco de anticorpo (adcs) com inibidores de ksp
MX2012014521A (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion.
MX2016008138A (es) Sistema para el suministro transdermico de ingredientes activos.
MX2013013809A (es) Dispositivos expandibles con revestimiento de una composicion de paclitaxel.
MY163809A (en) Transdermal drug delivery system containing donepezil
MX2012002727A (es) Sistema terapeutico transdermico para administrar fentanilo o un analogo del mismo.
EP3300734A3 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
EA201391689A1 (ru) Система доставки лекарственного средства
BR112015011778A2 (pt) métodos para administrar e avaliar drogas de expulsão de nitrogênio para o tratamento de encefalopatia hepática
WO2014164285A3 (en) Use of levocetirizine and montelukast in the treatment of vasculitis
MX382776B (es) Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica.
BRPI0607172A2 (pt) método para a ministração de pelo menos uma substáncia farmaceuticamente ativa a um paciente, combinação de medicamentos e uso de pelo menos uma substáncia farmaceuticamente ativa para a fabricação de uma combinação de medicamentos
DK2802319T3 (da) Fastdosiskombinationsterapi for parkinsons sygdom
MX2013013808A (es) Dispositivos expandibles con revestimiento de una composicion de rapamicina.
HK1222585A1 (zh) 用於提供疼痛減輕和麻醉的二氫埃托啡
MX364652B (es) Formulacion farmaceutica que comprende ciclesonida.
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
BR112014018426A8 (pt) Composição e dispositivo para administração transdérmica, e, método para administrar uma progestina
PH12015501538A1 (en) Topical ocular analgesic agents
HK1223852A1 (zh) 睪丸酮凝膠組合物及相關方法
UA109944U (uk) Фармацевтична композиція для зниження рівня n-оксиду триметиламіну